You make an excellent point about risks and side effects.
Going back to the last March 7 Capital Markets 2024 where Novo Nordisk provided a progress update on its Strategic Aspirations 2025 (https://novo.evenzu.com/stream/cmd2024#312;)
Please watch the session on Cardiovascular & Emerging Therapy Areas presented by Martin Holst Lange, Executive Vice President, Development.
Listen from minute 3:30 to 3:50.
Although I had difficulty hearing him well because of his accent this is most of what he said in an unusually excited manner:
3:32 QUOTE Obviously, for us it is nice to take XXXX departure XXX XXXXX XXX. Talked about that earlier today, moving into a new therapy area, having a molecule already in the market that decreases the risk of MACE, improves cardiovascular, but also all causes mortality; particularly thinking about the ASCVD space, it’s incredible UNQUOTE
Two questions come to mind:
1) to what molecule was he referring?
2) Could Novo Nordisk’s goal to establish a presence in the cardiovascular space in 2025, and Amarin’s BOD objective to “accelerate operational momentum”, that is execution in the short-term, converge?
As a reminder, it is the next day, on March 8, that FDA approved the weight-loss drug Wegovy for lowering the risk of stroke and heart attack in overweight and obese adults who do not have diabetes.
News 
Market Data 
Discover 
